
Beyond one and done: engineering durable, redosable cell‑based gene therapies
17/6/2026
0:00
18:34
The one‑and‑done model has defined gene therapy for a generation. Chris Hopkins thinks it is time to move on. At ASGCT 2026, Abi Pinchbeck spoke with the Co‑founder and CEO of Glafabra Therapeutics on redoseable cell‑based gene therapy, a platform spanning Fabry, Pompe, and Gaucher diseases, and what durable, if not permanent, treatment could mean for patients. A podcast version of this discussion is also available.
Altri episodi di "The BioInsights Podcast"



Non perdere nemmeno un episodio di “The BioInsights Podcast”. Iscriviti all'app gratuita GetPodcast.








